

06 September 2024

Treatment of cancers

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	49
1.2 Alpelisib (Piqray)	<5 (+Fulvestrant = <5 patient)
1.3 Fulvestrant (fulvestrant or Faslodex)	15
1.4 Palbociclib (Ibrance)	49
1.5 Ribociclib (Kisqali)	33
1.6 Capivasertib (Truqap)	<5

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Number patients treated
Not available

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
3.1 Curative	Not available
3.2 Palliative	Not available
3.3 Not known / stated	49

06 September 2024

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	6
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	13
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	<5

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of April 2024 and end of June 2024?

Type of breast cancer	Number patients treated
5.1 all types of breast cancer	<5
5.2 adjuvant treatment for early breast cancer	Not available

PROSTATE CANCER

Q6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Abiraterone (Zytiga or generic abiraterone)	52
6.2 Apalutamide (Erleada)	29
6.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5 (+prednisolone = <5 patients)
6.4 Darolutamide (Nubeqa)	10
6.5 Enzalutamide (Xtandi)	118

Q7. How many patients were treated with these products specifically for **prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?**

06 September 2024

Name of medicine	Number patients treated
Docetaxel for prostate cancer	<5 (+prednisolone = 10patients) (+darolutamide = <5patients)
Olaparib (Lynparza) for prostate cancer	<5

Q8. How many patients were treated with the following medicine combinations in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Of note ADT is prescribed in the community so not available on RISOH.

Name of medicine	Number patients treated
8.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	Not available
8.2 Apalutamide (Erleada) + Androgen Deprivation Therapy	Not available
8.3 Darolutamide (Nubeqa) + Docetaxel + ADT	Not available (Darolutamide+Docetaxel = <5 patients)
8.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy	Not available
8.5 Olaparib (Lynparza) + Abiraterone	<5

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

OVARIAN and ENDOMETRIAL CANCERS

Q9. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
9.1 Dostarlimab (Jemperli)	<5
9.2 Niraparib (Zejula)	59
9.3 Rucaparib (Rubraca)	6
9.4 Olaparib (Lynparza)	22

06 September 2024

Q10. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
10.1 Olaparib in total	22
10.2 Olaparib monotherapy	22
10.3 Olaparib + bevacizumab in combination	<5
10.4 Bevacizumab total	13
10.5 Bevacizumab monotherapy	<5
10.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	11

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.